GeneDx Holdings Corp Celebrates GUARDIAN Study Recognition by JAMA

On December 15, 2025, GeneDx (Nasdaq: WGS), a frontrunner in genomic diagnostics, proudly announced that its landmark GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been featured in the *Journal of the American Medical Association* (JAMA) as part of its prestigious Research of the Year Roundup. This accolade underscores the study’s vital contributions to the field of genomic screening, marking a significant advancement in the identification of rare childhood conditions.

The GUARDIAN study is recognized for its groundbreaking findings demonstrating the efficacy of genomic newborn screening (NBS) in identifying serious and actionable health conditions in infants, surpassing the capabilities of traditional NBS. Key statistics from the analysis of the first 4,000 newborns enrolled reveal:

Among the critical conditions identified were long QT syndrome, Wilson disease, and severe combined immunodeficiency (SCID), all of which benefit significantly from early intervention. For instance, long QT syndrome, a rare cardiac disorder, can be effectively managed through timely treatment, thus preventing potentially fatal outcomes.

Dr. Wendy Chung, the principal investigator of GUARDIAN and Chief of Pediatrics at Boston Children’s Hospital, expressed pride in the recognition, stating, “This honor reflects the dedication of the entire GUARDIAN team and the families who participate. GUARDIAN demonstrates that genomic screening can identify serious childhood conditions earlier than ever before.”

Katherine Stueland, President and CEO of GeneDx, echoed this sentiment, emphasizing how the GUARDIAN study is setting a new standard for integrating genomics into newborn care. “Earlier, more precise genetic diagnosis can fundamentally change the trajectory of a child’s life,” she stated.

The GUARDIAN study represents one of the largest genomic newborn screening initiatives globally, with over 20,000 newborns screened thus far and an ultimate goal of enrolling 100,000 infants. This ambitious program is not only focused on enhancing early diagnosis but also aims to evaluate the feasibility and equity of genomic screening alongside conventional public health programs.

Dr. Rudolph Leibel, Chief of Pediatric Molecular Genetics at NewYork-Presbyterian/Columbia University, highlighted the transformative potential of genomic analysis in personalizing medical care from birth. “These same genetic data can inform diagnostic and therapeutic decisions throughout a child’s life,” he noted.

The GUARDIAN initiative is a collaborative endeavor involving Columbia University, NewYork-Presbyterian, the New York State Department of Health, and Illumina, which provides the sequencing technology. This collaboration aims to generate critical evidence and inform future policies regarding newborn screening and precision medicine.

As the GUARDIAN study progresses, it is set to reshape pediatric healthcare, allowing for timely interventions that can drastically improve health outcomes for children. The advantages of next-generation sequencing technologies are increasingly evident, and with JAMA’s recognition, the potential impact on newborn screening practices is poised to grow.

GeneDx's GUARDIAN study’s recognition by JAMA is a significant milestone, spotlighting the importance of genomic insights in modern healthcare. As the field of genetics continues to evolve, GUARDIAN stands at the forefront, paving the way for a future where early diagnosis and intervention become the norm, transforming the landscape of pediatric medicine.